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Abstract
The identification of molecular target and mechanism of action of compounds is a key hurdle in drug discovery.
Multiplexed techniques for bead-based expression profiling allow the measurement of transcriptional signatures of
compound-treated cells in high-throughput mode. Such profiles can be used to gain insight into compounds’
mode of action and the protein targets they are modulating. Through the proxy of target prediction from such
gene signatures we explored important aspects of the use of transcriptional profiles to capture biological variability
of perturbed cellular assays. We found that signatures derived from expression data and signatures derived from
biological interaction networks performed equally well, and we showed that gene signatures can be optimised
using a genetic algorithm. Gene signatures of approximately 128 genes seemed to be most generic, capturing a
maximum of the perturbation inflicted on cells through compound treatment. Moreover, we found evidence for
oxidative phosphorylation to be one of the most general ways to capture compound perturbation.
Keywords: transcriptional profiling, target prediction, genetic algorithm, graphics processing unit (GPU) program-
ming, compute unified device architecture (CUDA)
Introduction
Early drug discovery research involves target discovery
and lead discovery. Target discovery is concerned with
the identification and validation of the disease-relevance
of a particular protein. Subsequent lead discovery is the
task of finding a suitable molecule that can interact with
the target in a specific, therapeutically relevant way. A
typical strategy to identify potential lead compounds is
the screening of large collections of molecules, up to
several millions, in highly automated high-throughput
assays. In biochemical assays, each molecule is tested
against a purified target protein of interest; molecules
that are found to significantly affect the assay readout
are called hits and are selected for further follow-up
experiments such as secondary- or counter-screens. Suc-
cessful outcomes in those latter screens result in more
confidence of having found a true modulator of the tar-
get protein, yielding a target-lead pair. An orthogonal
approach where the target protein is unknown from the
outset is a phenotypic screen: a collection of molecules
is tested for their potential to induce (or abrogate) a
complex phenotype, such as the ability of cells to divide
successfully. Because the target protein of such screens
is not known, they require the identification of the tar-
get that gives rise to the observed phenotype subsequent
to the identification of active compounds.
Whereas biochemical assays have the advantage that
the target protein is essentially a parameter of the
experiment, they often lack biological relevance because
compounds tested do not have to penetrate cell walls
and are not subjected to other relevant biological pro-
cesses such as active transport and metabolism. Pheno-
typic assays are a more realistic model for compound
administration to living systems but entail the significant
post-screen difficulty of target identification and mode
of action (MoA) elucidation for any hits identified.
The identification of molecular target and MoA of
compounds is a key hurdle in drug discovery. Signifi-
cantly more hits are obtained from screening campaigns
than are typically amenable to extensive experimental
profiling such as proteomics. Computational methods
that inform about the underlying, specific biological
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processes, for example targets and pathways, that are
actually being perturbed by the compounds are much
sought after, as they can help to uncover the molecular
causes of the positive assay readout. Many such methods
rely on the availability of compound annotations from
previous experiments or specific profiling platforms.
There is a considerable amount of literature on target
prediction methods that work from chemical structure
alone or composite data types using a variety of meth-
ods, and we refer the interested reader to [1-4] and the
references therein. Profiling platforms are composed of
a reference base of n-dimensional readouts, for example
a panel of reporter gene assays [5], for a set of well-
characterised compounds and a mechanism to position
the readouts of novel samples in the context of the
reference. This latter mechanism is often some kind of
metric such as Euclidean distance or Pearson correla-
tion, though more sophisticated methods can also be
applied.
Transcriptional profiles, the mRNA levels of expressed
genes as a result of treatment of cells with a compound,
are routinely used to cluster or otherwise relate com-
pounds that elicit a similar biological response [6-8]. For
any such approach, it is important to choose which
genes to include in the calculations. Typical human gen-
ome-wide chips cover approximately 22,000 genes,
where the expression level of each gene is determined
by a set of specific probes, a probeset [9]. Other experi-
mental techniques, however, require the selection of a
set of genes upfront, for example the Luminex technol-
ogy of Panomics [10]. The selection of suitable genes, a
gene signature, depends on the desired signature size,
which is directly proportional to cost, as well as the bio-
logical questions that need to be addressed. The selec-
tion and evaluation of such gene signatures is the
subject of the remainder of this article. Like many other
companies, Novartis has several compound profiling
platforms, including one based on expression profiles.
The questions that we addressed in this article are
directly related to some of our ongoing efforts to opti-
mise such platforms.
We used a publicly available microarray dataset [7] in
conjunction with extensive compound annotations to
probe several important aspects of target and MoA pre-
diction from gene signatures. We explored systemati-
cally to what extent transcriptional profiles of
compounds can be used for target prediction. This
study provided insight into questions such as the follow-
ing: Is there and what is the minimal gene signature that
can be used to reasonably predict molecular targets of
compounds? Do designed signatures predict targets bet-
ter than genes selected at random? How can such signa-
tures be optimised in an automatic way, and what are
the results of such an optimisation? We employed
machine learning and biologically inspired algorithms
implemented on state-of-the-art graphics processing
units (GPUs) to answer these questions.
Results and discussion
Compound-target annotations
We retrieved all currently known targets for any com-
pound in Connectivity Map 2 [7] where the compound
had an activity (IC50, Ki) of ≤ 5 μM. Each compound
had an average number of 23 targets satisfying these cri-
teria. The compound with the most targets was stauros-
porine with 386, whereas for 126 molecules only one
target was known, for example hydroxysteroid (17-beta)
dehydrogenase 1 (HSD17B1) for the horse steroid equi-
lin. At least 5 targets were known for 502 compounds.
These high numbers of high-affinity targets per com-
pound illustrate the fact that many compounds, includ-
ing many marketed drugs [4,11], are much less specific
than is typically appreciated. A further compounding
factor for this polypharmacology comes from the tissue
expression of the drug targets. A compound with several
high-affinity in vitro targets could not manifest its action
at all of these proteins if most of them were not
expressed. The tissue expression of many proteins, how-
ever, is relatively unspecific: recent RNA-sequencing
experiments showed that approximately 6,000 genes
were expressed in all of heart, liver, testis, skeletal mus-
cle and cerebellum, all of which are important target tis-
sues for therapeutics [12,13]. Targeted drug delivery and
carefully designed pharmacokinetic compound proper-
ties can provide some relief; yet, it is obvious that the
foundations for polypharmacology have been laid in
evolutionary history [14], and that the man-made design
of exquisitely specific drugs is a tremendous
undertaking.
A common problem encountered by modellers of che-
mogenomics data (large repositories of compound-target
associations) that is equally a common concern for
reviewers of such modelling exercises is the extreme
sparseness of the compound-target matrix. The nature
of compound screening in drug discovery brings with it
that often many structurally similar compounds are
tested against the same target, or target family, to iden-
tify structural determinants of activity and selectivity.
This results in disproportionately many data points for
isolated proteins, whereas other proteins are relatively
deprived of the honour of being probed to that extent
[15]. Consequently, every single chemogenomics dataset,
with few exceptions such as the BioPrint database from
CEREP [16], is unbalanced and sparse. This is a severe
drawback from a modelling perspective as most likely
any number for false positives can be expected to be an
overestimate. The dataset we used comprises 1,309 com-
pounds and for 804 of these we had target annotations
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in our repository. These annotations covered a total of
4,428 distinct proteins (as identified by their UniProt
primary accessions) in a total of 19,871 compound-tar-
get associations. Thus, merely 0.5% of the compound-
target matrix that we base our studies on is populated.
This extreme sparseness is sobering at best considering
that we retrieved the annotations from one of the largest
existing repositories of compound bioactivities. Conver-
sely, it illustrates straightforwardly that there is ample
space for novel discoveries.
Target prediction from gene signatures
We used a simple nearest neighbour technique to pre-
dict targets of compounds. To that end, we correlated
the transcriptional profile of a query compound to all
other profiles and retained the three nearest neighbours,
that is the compounds corresponding to the three high-
est correlations. The targets of the neighbours are the
predicted targets, and we consider a prediction success-
ful if the intersection of predicted and real targets is
non-zero. The overall accuracy for a given signature is
the fraction of successful predictions; see section ‘Mate-
rials and methods’ for details. Unless otherwise stated,
accuracy refers to the accuracy obtained when only the
first nearest neighbour is considered.
The term transcriptional signature is used for a subset
of all probesets that is employed for the target predic-
tions. Such signatures were derived using two data-dri-
ven methods: (1) based on all expression values; and (2)
based on biological networks. For the latter part, we
used all human interactions of the StringDB interaction
database [17]. We retained the top-ranking 300 probe-
sets for each of the selection methods described in sec-
tion ‘Methods and materials’. This cutoff was chosen as
even for randomly selected signatures there was no
increase in performance with more probesets (see next
paragraph and Figure 1).
To establish a baseline for all further experiments,
we determined the accuracy of guessing by using ran-
domly shuffled compound-target associations. The
accuracy obtained in this way ranges between 0.11 for
one nearest neighbour and 0.26 for three nearest
neighbours. It is interesting to note that even randomly
selected probesets perform better than pure chance, for
example with one nearest neighbour 0.11 versus 0.16
(Figure 1).
Figure 1 Performance of random signatures levels off at around 300 probesets. The dotted lines are the accuracies obtained (for
increasing number of nearest neighbours from bottom to top) for randomly shuffled compound-target associations. This shows that although
the signature probesets were selected randomly, they nonetheless yield a better target prediction accuracy than chance alone. One nearest
neighbour: cross; two nearest neighbours: triangle; three nearest neighbours: square. Displayed data are the average accuracy values (n = 50)
and the total length of the error bars is the corresponding standard deviation.
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Designed signatures
We used two different groups of signatures for our
experiments: one group was derived from the expression
data itself, the other from biological interaction net-
works. Regardless of how the signatures were obtained,
none produced an accuracy above 0.27. All signatures
that were derived using expression data had accuracies
in the range of 0.13 (for the minimum variance signa-
ture) to 0.26 (for the maximum variance signature, see
Figure 2). Even with three nearest neighbours, the mini-
mum variance signature was clearly the worst (Figure 2).
The signature most different from all others consisted of
the minimum variance probesets. This was consistent
with what would be expected, as the genes correspond-
ing to these probesets simply were not very responsive
to perturbation. It is interesting to note that the genes
that had the highest average expression were not very
predictive; on the contrary, the signature comprised of
the probesets that had the lowest average expression
performed better. Consistent with the previous observa-
tions was that the probesets with the highest overall var-
iance of expression were most useful for target
prediction.
The signatures derived from biological networks all
performed equally with accuracies around 0.23; all of
them improved in a similar way with increasing num-
bers of nearest neighbours (Figure 3). The signature that
performed best was based on the betweenness centrality
of network nodes. This centrality is related to the num-
ber of shortest paths that go through a node. None of
these signatures performed better than any signature
derived from expression data.
Genetically optimised signatures
We used a genetic algorithm to evolve pools of 200 ran-
domly initialised signatures for 150 generations. This
resulted in an optimised set of genes for each signature
size. Figure 4 shows the distribution of fitness scores
over the range of the entire optimisation of 150 genera-
tions for a signature of 64 probesets. The decrease in
the rate of improvement of the maximum fitness indi-
cates that the genetic algorithm is close to converging
to an optimal solution. Whereas there is no guarantee
that it will ever be reached [18], Figure 4 shows that we
are presumably very close to the maximally achievable
accuracy for that signature size.
Figure 2 Performance of the signatures derived from expression data for one, two or three nearest neighbours (NN). maxavg: highest
mean expression; minavg: lowest mean expression; maxvar: highest standard deviation; minvar: lowest standard deviation; maxabs: highest mean
of absolute expression value; minabs: lowest mean of absolute expression value and shannon: Shannon entropy of binned expression values.
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Overall, all of the genetically optimised signatures
achieved accuracies above 0.26. Therefore, the smallest
optimised signature with 32 probesets outperformed
many of the expression-based signatures and also all
network-based signatures. The signature that performed
best contained 128 probesets and achieved an accuracy
just below 0.30.
An analysis of the overlap of selected probesets
between all of the optimised signatures revealed that
very few probesets are shared. The highest overlap is
achieved between the two largest signatures with 136
shared probesets between the signatures with sizes 1,448
and 2,048. The maximum overlap between two signa-
tures is equal to the size of the smaller signature. There-
fore, overlaps are expressed here as the fraction of the
smaller signature that is common to the larger signa-
ture. The largest fractional overlap is between the signa-
tures of sizes 256 and 2,048: 37 probesets (14%) of the
smaller signature are found in the larger signature.
Even the smallest genetically optimised signature (32
probesets) performed basically equally well as the best
performing signature derived from expression values (the
300 most variable probesets). Each of the 32 probesets of
the smaller signature therefore seems to capture at least
10% more information than the 300 probesets of the lar-
ger signature. It can also be noted that these two signa-
tures only share one probeset. The smaller, optimised
signature is therefore not merely a result of the genetic
algorithm choosing the most variable probesets.
The good performance of very small, optimised signa-
tures as well as the trend seen in Figure 5 indicates that
larger signatures do not help in target prediction using
our approach. Contrarily, they seem to add noise that is
detrimental to performance. Obviously, such a trend
might not be observed for other target prediction
approaches such as reverse causal reasoning [19] where
a larger signature might indeed provide more informa-
tion to seed the reasoning algorithms.
Analysis of gene signatures
We analysed whether the signatures derived by data-dri-
ven processes or the genetic algorithm are representative
of any major biological processes. To that end, we calcu-
lated pathway enrichments for the designed signatures
and the best-performing optimised signature with 128
probesets.
Figure 3 Performance of the signatures derived from biological networks for one, two or three nearest neighbours (NN). betweenness:
betweenness centrality; closeness: closeness centrality; degree: degree centrality; in-degree: in-degree centrality; out-degree: out-degree
centrality; tfregdiv: diverse set of genes that are downstream of regulators of gene expression.
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Overall, the signatures of the genes that have the high-
est absolute and highest mean expression yielded the
most significant enrichments. The two most significantly
enriched pathways were oxidative phosphorylation
(-logp ~ 100) and ubiquinone metabolism (-logp ~ 58).
The p-values increase rapidly to 10-5 within the top five
ranked pathways. The best-performing expression-based
signature is enriched for cytoskeleton remodelling, regu-
lation of cell cycle checkpoint G1/S and regulation of
cellular metabolism (-logp values between 10 and 8).
The only other very significant enrichments were
obtained with the network-derived signature based on
the betweenness centrality of nodes. The enriched path-
ways were involved in protein folding (p ~ 10-19) and
regulation of G1/S transition (p ~ 10
-18). Noteworthy
enrichments were also found for the signatures based
on the degree centrality of nodes in the interaction net-
work. All three of these signatures (degree, in-degree
and out-degree) yielded several highly enriched path-
ways for nucleotide metabolism (10-20 <p < 10-17). The
results of all the enrichment calculations are provided as
an Excel spreadsheet, see additional file 1.
The best-performing optimised gene signature with
128 genes showed a similar result as the one obtained
for the highest absolute and highest mean expression
signatures: oxidative phosphorylation (10-113 <p < 10-76)
and ubiquinone metabolism (p ~ 10-64) were consis-
tently the most significant pathways across several of
the optimised signatures from different runs of the
genetic algorithm.
The low p-values for oxidative phosphorylation are
due to the large size of this pathway compared to all
other pathways. This pathway contains several large
complexes of the respiratory chain (mammalian com-
plexes 1 to 4 and ATP synthase) and is composed of a
total of 105 proteins. The ubiquinone metabolism path-
way counts 74 proteins, 46 of which pertain again to
mammalian complex 1. The constituents of the oxida-
tive phosphorylation pathway, especially so the parts of
the electron transport chain composed of complexes 1
to 4, are highly expressed in the mitochondria of all
cells. Furthermore, rapidly dividing cancerous cells in
culture, such as the ones used to derive the expression
values used in this study, also require a lot of energy;
Figure 4 Results of optimisation by a genetic algorithm of the signature with 64 probesets. The vertical line for each iteration spans the
range from worst to best fitness. The solid line indicates the mean fitness of all individuals in any iteration.
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thus, high expression levels are to be expected for mem-
bers of the respiratory chain. Naturally, such highly
expressed genes were selected for inclusion into the sig-
nature of genes with highest expression, which in turn
explains the observed enrichment.
A more intriguing fact is that the same enrichment is
observed for the best-performing optimised signature.
This suggests that there is at least some overlap in the
functionality of the genes of the two signatures: given
the large size of the mammalian complexes 1 to 4 there
need not be an overlap of the same genes, but in genes
that belong to the same complex. The optimised signa-
ture therefore contains a significant part of genes that
have a high level of expression overall, whereas the
other genes were selected by the algorithm for other
reasons. These other reasons are likely to remain
unfounded due to the inherent lack of interpretability of
results obtained from genetic optimisations, and we do
not intend to speculate about those reasons at this point
and leave this for further study. We note, however, that
the enrichments obtained for the optimised signature
are fundamentally different from and much more
significant than those for an equal number of randomly
selected probesets (data not included).
Conclusion
We established a baseline for achievable target predic-
tion accuracy using a simple ‘guilt-by-association ’
method based on correlation of transcriptional profiles.
The main objective of this study, however, is not target
prediction per se but an investigation about how this
can be achieved with gene signatures of varying nature
and length. Two distinct groups of transcriptional sig-
natures—expression data driven and based on biologi-
cal interaction networks—were analysed for their
performance; no striking differences between these
groups were found. The optimisation of transcriptional
signatures by a genetic algorithm led to the best-per-
forming signatures and indicated that a maximum size
of approximately 128 probesets is optimal. A signature
of this size therefore extracted a maximum of biologi-
cal variation of the investigated cellular systems. The
genes of this optimised signature were predominantly
found in pathways relating to oxidative
Figure 5 Accuracies of signatures after 150 rounds of evolution by a genetic algorithm. Maximum accuracy is achieved by a signature
size of 128 probesets.
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phosphorylation and ubiquinone metabolism; this indi-
cated that these biological processes might be the most
generic way to capture compound perturbation of
cells. We furthermore showed that it is possible to
optimise very small signatures (32 probesets) for a par-
ticular purpose. Given that both groups of signatures—
expression-based and network-based—perform simi-
larly it is to be expected that a combination of both
can lead to better signatures.
Methods and materials
Expression data and compound annotations
Our analyses are based on gene expression data from
the Broad Institute’s Connectivity Map 2 (CMAP2) [7].
Several cell lines were treated with a total of 1,309 dif-
ferent compounds and whole-genome expression levels
were determined using Affymetrix gene chips. The cell
lines with most measurements in CMAP2 were the
human breast epithelial adenocarcinoma cell line MCF7,
the prostate adenocarcinoma cell line PC3 and the
human promyelocytic leukaemia cell line HL60. Expres-
sion levels were measured using the human Affymetrix
chips (HT)HG-U133A [9]. The compounds were tested
in batches with replicates, resulting in a total of 6,100
experiments. The combination of a compound, applied
concentration, cell line and microarray platform used is
referred to as a treatment instance.
We used a total of 22,267 probesets that were present
in all treatment instances. CMAP2 data were down-
loaded from the Broad Institute’s website and processed
in R [20] using the affy [21] package. Robust multichip
average [22] expression values were calculated for each
treatment instance, and the expression values of each
batch containing more than five treatment instances
were then mean-centred on a probeset level using the
average expression of each probeset in the correspond-
ing batch [12]. In other words, the expression values we
used correspond to expression after treatment relative
to average expression in the batch; expression of vehicle
(DMSO) treated cells does not enter the process. This
procedure, originally proposed by Iskar et al. [12], has
been found to be suitable for the elimination of batch
effects for purposes very similar to ours.
The targets of any compound used in CMAP2 were
obtained from an in-house bioactivity repository that
comprises information both proprietary to Novartis and
public such as ChEMBL and DrugBank [23,24]. We
retained all targets of a compound at which it had an
IC50 or Ki value of ≤ 5 μM.
Target prediction and accuracy measure
We determined nearest neighbours for each treatment
instance by searching for treatments with highly corre-
lated (Pearson product-moment correlation coefficient)
gene signatures. Because the same molecule might have
been tested several times under slightly different condi-
tions (for example varying concentration, different cell
line, different array platform), the nearest neighbour
search was implemented in a way that prohibits it from
finding a variation of a molecule as a neighbour for that
molecule. The accuracies obtained would be higher
without this restriction, but this would overestimate the
true value that can be achieved in a real-world setting:
in terms of target prediction the knowledge gained from
a self-match is zero. We determined a maximum of
three nearest neighbours for each treatment instance.
All of our analyses were assessed using the accuracy of
target prediction, that is the fraction of all predictions
that are considered successful. We considered a target
prediction successful if the intersection of the target sets
of query and nearest neighbour(s) is not empty. The
main reason for this measure is the sparseness of com-
pound-target annotations: any other measure would
result in misleadingly low performance measures due to
the large number of false positives/negatives; however,
many of those predictions could actually be true if a
complete compound-target matrix were available. An
equally important factor for such a performance metric
is the fact that in our setting all predicted targets have
an equal rank. This is in contrast to other methods that
provide a ranked list of targets. In separate experiments
(not included here) we also used the F-measure, a
weighted average of positive recall and positive precision
that can be tuned to favour either recall or precision.
The reliance on accuracy alone provides a realistic
assessment of an achievable baseline for target predic-
tion. Nevertheless, for certain applications it might
indeed be worth to use other performance measures, for
example to find a signature that minimises false nega-
tives. For the precision of target prediction for the
designed signatures, please refer to additional file 2.
The correlation calculations and nearest neighbour
algorithms were implemented as a Python module using
cython and CUDA on an NVIDIA GPU Tesla M2050
with 448 cores. This resulted in a speedup of more than
two orders of magnitude compared to a single CPU
implementation. The speed of this implementation was
essential to get results from the genetic algorithm proce-
dure in a reasonable amount of time. The source code
used for any of the calculations is available from the
authors upon request.
Signature selection
In addition to designed signatures, we used signatures
that were made up of randomly selected probesets to
estimate the improvement that can be achieved when
designed signatures are employed. We used 17 signa-
tures containing 16 to 4,096 probesets in half-
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logarithmic steps in base 2. The signature sizes used
were thus 16, 22, 32, 45, 64, 90, 128, 181, 256, 362, 512,
724, 1024, 1448, 2048, 2896, 4096. We randomly
sampled 50 different signatures for each signature size;
the reported accuracies for these signatures are therefore
sample averages.
For expression-based signatures, the probesets were
ranked according to the following criteria determined
across all expression arrays in CMAP2: (1) highest mean
expression; (2) lowest mean expression; (3) highest stan-
dard deviation; (4) lowest standard deviation; (5) highest
mean of absolute expression value; (6) lowest mean of
absolute expression value and (7) Shannon entropy of
binned expression values; expression values were binned
into 200 bins in the range [-5, 8].
For network-based signatures, we used the following
criteria to score network nodes: (1) betweenness central-
ity; (2) closeness centrality; (3) degree centrality; (4) in-
degree centrality; (5) out-degree centrality; (6) maximum
average distance to reachable transcriptional modifiers.
The motivation for the last signature was to have a
diverse set of genes that are downstream of regulators
of gene expression. We first identified all regulators of
gene expression (regulatory nodes) as any node in
StringDB [17] that has at least one outgoing edge of
mode ‘expression’. For all nodes downstream of any reg-
ulatory node we then determined the average shortest
path length to all reachable upstream regulators. Over-
all, this results in a total of 13 designed signatures.
Optimisation with genetic algorithm
We used a genetic algorithm to determine an optimal
signature for a given number of probesets. A population
of 200 randomly initialised signatures was evolved for
150 generations. The objective function maximised by
the genetic algorithm is the accuracy of prediction as
defined above. The top 20% of each iteration were
included for any subsequent iteration (elitism), the
remaining 80% were obtained through crossover and
mutation operations (crossover rate 70%, mutation rate
30%). Genetically optimised signatures were derived for
the following signature sizes: 32, 45, 64, 90, 128, 181,
256, 362, 512, 724, 1024, 1448, 2048. The genetic algo-
rithm was based on an example in ‘Programming collec-
tive intelligence’ [25].
Pathway enrichments
We used GeneGO (now part of Thomson Reuters)
Metacore to calculate pathway enrichments. This calcu-
lation is based on a hypergeometric null distribution for
the intersection of the query set of genes and any given
pathway [26]. The p-value corresponds to the probabil-
ity of an intersection equal or greater to the observed
one. This procedure is equal to a Fisher’s exact test.
Additional material
Additional file 1: Pathway enrichment for the designed gene
signatures. Pathway enrichment for the designed gene signatures.
Additional file 2: Precision of prediction for designed signatures.
Excel spreadsheet with precision of prediction for designed signatures.
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